Close Menu

coronavirus

Breaking news on coronavirus testing, with real-time reporting on assays to detect the SARS-CoV2 coronavirus, which causes COVID-19. 

Check out our Coronavirus Test Tracker for the latest information on the regulatory status of these tests in the US, European, and Asian markets.

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.

The guideline, in effect for three months, gives access to many molecularly informed indications that NICE previously found not cost-effective or that it hasn't yet reviewed.

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.

Health systems' molecular testing labs haven't had to cut back on genomic profiling for cancer patients yet but may need to accommodate COVID-19 testing if needed.

Many companies and counselors see the COVID-19 pandemic as a catalyst for moving germline risk testing into a digital-first healthcare model.